Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26555615 | 1.00 | GSR (0.55) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL29775136 | 1.00 | GSR (0.55) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL30254803 | 1.00 | GSR (0.55) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL30797910 | 0.97 | GSR (0.51) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL30798022 | 0.97 | GSR (0.51) | GSRFOLH1DPP8DPP9DPP7 | |
| Glycine SCHEMBL29096238 | 0.97 | GSR (0.51) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL30414807 | 0.95 | GSR (0.50) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL30242742 | 0.95 | GSR (0.50) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL24171145 | 0.95 | GSR (0.47) | GSRFOLH1DPP8DPP9DPP7 | |
| SCHEMBL29812490 | 0.95 | GSR (0.47) | GSRFOLH1DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268808-A1 | TOPICAL COMPOSITION AND METHOD OF USE | ALLERGAN SALES, LLC (US) | 2025-08-28 | — | — | US | claimed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| WO-2025067293-A1 | HELICASE AND USE THEREOF | 北京齐碳科技有限公司 | 2025-04-03 | — | — | WO | claimed |
| CN-119709689-A | Helicase and application thereof | 北京齐碳科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-12171859-B2 | Topical composition and method of use | ALLERGAN SALES, LLC (US) | 2024-12-24 | — | — | US | claimed |
| CN-118660707-A | Supermolecule self-assembly system | 北京睿创康泰医药研究院有限公司 | 2024-09-17 | — | — | CN | claimed |
| WO-2023193244-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | 北京睿创康泰医药研究院有限公司 | 2023-10-12 | — | — | WO | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| US-20220387284-A1 | TOPICAL COMPOSITION AND METHOD OF USE | ALLERGAN SALES, LLC (US) | 2022-12-08 | — | — | US | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| EP-3303598-A1 | TARGETED LIPID PARTICLES FOR SYSTEMIC DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES | Ramot at Tel-Aviv University Ltd. (IL) | 2018-04-11 | — | — | EP | claimed |
| WO-2016189532-A1 | TARGETED LIPID PARTICLES FOR SYSTEMIC DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-12-01 | — | — | WO | claimed |
| WO-2026090007-A2 | SYSTEMS AND METHODS FOR ANALYTE PROCESSING | PRIMARY BIOSCIENCE, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260069711-A1 | SYSTEMS, DEVICES AND METHODS FOR MODULAR FUNCTIONALIZED CELLULAR NANOSTRUCTURES FOR TARGETED PAYLOAD DELIVERY | UNIV CALIFORNIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-11241485-B2 | PDE5 compositions and methods for immunotherapy | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| WO-2021256546-A1 | METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS | 味の素株式会社 | 2021-12-23 | — | — | WO | disclosed |
| CN-110075113-A | Immune response is stimulated by the enantiomer of cation lipid | PDS生物科技公司 | 2019-08-02 | — | — | CN | disclosed |
| CN-105163753-B | Cationic lipid vaccine compositions and methods of use | PDS生物科技公司 | 2018-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | IL2, IFNG, ICOS | GSR 4364/4885FOLH1 227/4885DPP8 3462/4885 |
| US-20260069711-A1 | SYSTEMS, DEVICES AND METHODS FOR MODULAR FUNCTIONALIZED CELLULAR NANOSTRUCTURES FOR TARGETED PAYLOAD DELIVERY | ILK, CD47, NAPA | GSR 4693/4885FOLH1 1176/4885DPP8 898/4885 |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | GSR 616/4885FOLH1 2410/4885DPP8 2274/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | GSR 4624/4885FOLH1 387/4885DPP8 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.